Combination Epigenetic Therapy Has Efficacy in Patients with Refractory Advanced Non–Small Cell Lung Cancer
Lovelace Respiratory Research Institute · Johns Hopkins University · +1 more institution
Abstract
UNLABELLED: Epigenetic alterations are strongly associated with the development of cancer. We conducted a phase I/II trial of combined epigenetic therapy with azacitidine and entinostat, inhibitors of DNA methylation and histone deacetylation, respectively, in extensively pretreated patients with recurrent metastatic non-small cell lung cancer. This therapy is well tolerated, and objective responses were observed, including a complete response and a partial response in a patient who remains alive and without disease progression approximately 2 years after completing protocol therapy. Median survival in the entire cohort was 6.4 months (95% CI 3.8-9.2), comparing favorably with existing therapeutic options.…
Citation impact
- FWCI
- 19.55
- Percentile
- 100%
- References
- 65
Authors
19- RARosalyn A. JuergensCorresponding
Lovelace Respiratory Research Institute, Johns Hopkins University, National Cancer Institute
- JWJohn Wrangle
Lovelace Respiratory Research Institute, Johns Hopkins University, National Cancer Institute
- FPFrank P. Vendetti
Lovelace Respiratory Research Institute, Johns Hopkins University, National Cancer Institute
- SCSara C. Murphy
Lovelace Respiratory Research Institute, Johns Hopkins University, National Cancer Institute
- MZMing Zhao
Lovelace Respiratory Research Institute, Johns Hopkins University, National Cancer Institute
Topics & keywords
- Epigenetic therapy
- Azacitidine
- Epigenetics
- Medicine
- Lung cancer
- Oncology
- Cancer
- Internal medicine
- Good health and well-being